Results 201 to 210 of about 396,895 (313)

Inconsistent medication recommendations for immune-mediated inflammatory diseases across pregnancy, lactation, and paternal preconception: a guideline-based review. [PDF]

open access: yesFront Pharmacol
Van den Broeck E   +11 more
europepmc   +1 more source

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen   +14 more
wiley   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

open access: yesArthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Major Challenges in Rheumatology: Will We Ever Treat Smarter, Instead of Just Harder?

open access: yesFrontiers in Medicine, 2019
Vasco C. Romão   +3 more
doaj   +1 more source

Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvement. [PDF]

open access: yesRheumatology (Oxford)
Ross L   +28 more
europepmc   +1 more source

Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Interlukin‐5 (IL‐5) plays a crucial role in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) by promoting eosinophil differentiation, activation, and survival. We present here a typical case of EGPA in which treatment with IL‐5 pathway inhibitors is prescribed, showing to be beneficial for the patient.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

Association of Type III and Type VI Collagen Neoepitopes With Disease Severity in Systemic Sclerosis. [PDF]

open access: yesJ Rheumatol
Ayla AY   +30 more
europepmc   +1 more source

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

open access: yes, 2020
Bathon, J.   +16 more
core   +1 more source

Home - About - Disclaimer - Privacy